Concepedia

Wim J. Tamminga

WJ

10

Publications

588

Citations

10

H-Index

1999

Active since

Affiliations

University of Groningen(Current)

AstraZeneca (Sweden)

Boehringer Ingelheim (Germany)

Xendo (Netherlands)

Utrecht University

Wim J. Tamminga is an author at University of Groningen specializing in medicine, pharmacology, and pharmacogenomics.

Top concepts

Publications per year

1999–2014

10

Publications

10

Absorption, Metabolism, and Excretion of Intravenously and Orally Administered [<sup>14</sup>C]Telmisartan in Healthy Volunteers

Joachim Stangier, Jochen Schmid, Dietrich Türck et al. · The Journal of Clinical Pharmacology · 2000 · 145 citations

CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences

Wim J. Tamminga, J. Wemer, B. Oosterhuis et al. · European Journal of Clinical Pharmacology · 1999 · 143 citations

, , +10

The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers

Wim J. Tamminga, J. Wemer, B. Oosterhuis et al. · European Journal of Clinical Pharmacology · 2001 · 99 citations

, , +5

Inhibitory Effect of Telmisartan on the Blood Pressure Response to Angiotensin II Challenge

Joachim Stangier, Chung‐An P. F. Su, P. N. M. van Heiningen et al. · Journal of Cardiovascular Pharmacology · 2001 · 44 citations

An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19

Wim J. Tamminga, Johan Wemer, B. Oosterhuis et al. · European Journal of Clinical Pharmacology · 2001 · 41 citations

, , +8

Rows per page

1–5 of 10